We agree with Kratina et al. (2023) that the problem of psychological suffering at the end of life deserves attention from a policy standpoint and that psychedelic therapies show promise in this clinical context. However, we argue the following in this rejoinder: (1) disproportionate attention to psychedelics may overstate the current evidence base, potentially diverting resources away from...
Beauchamp, T. L., and J. F. Childress. 2019. Principles of biomedical ethics. Oxford: Oxford University Press. Boyle, J. 2004. Medical ethics and double effect: the case of terminal sedation. Theoretical Medicine and Bioethics 25 (1):51–60. doi:10.1023/b:meta.0000025096.25317.22. Creutzfeldt, C. J., B. M. Kluger, and R. G. Holloway. 2019. Neuropalliative care: A guide to improving the lives of...
This piece stems from my own experience of a threshold consciousness that followed life-or-death surgery in 2015, when surgeons had informed me that I had only 2 days to live and offered me 2 days palliative care as an alternative choice. My survival of the surgery together with the experience of that threshold consciousness led me to a re-appraisal of my own practice in Dramatherapy. Out of my...
AbstractThere is a current debate in society as to whether depression can be a terminal illness. Meaning-centered psychotherapy (MCP) and psychedelic medicines have both been shown to treat existential distress in palliative care settings. We are reporting the case of a patient for whom MCP combined with ketamine was an effective treatment for his recurrent and severe depressive disorder with...
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its potential therapeutic benefits for psychiatric disorders, substance use disorders (SUD), and palliative care. While it is certain that more research is necessary as psychedelic-assisted therapy becomes more prevalent, it will most likely be future...
Recent research offers good reason to think that various psychedelic drugs-including psilocybin, ayahuasca, ketamine, MDMA, and LSD-may have significant therapeutic potential in the treatment of various mental health conditions, including post-traumatic stress disorder, depression, existential distress, and addiction. Although the use of psychoactive drugs, such as Diazepam or Ritalin, is well...
Psychedelische Substanzen haben sich über die letzten Jahre überraschend zu neuen Hoffnungsträgern für eine Verbesserung des Therapieerfolgs in der Behandlung verschiedener psychischer Erkrankungen entwickelt. Auslöser für die Renaissance psychedelischer Therapien waren nicht allein pharmakologische Innovationen der letzten Jahre, sondern auch eine steigende Ratlosigkeit angesichts...
The potential benefits and deficits of the chemical compound psilocybin, particularly when paired with psychotherapeutic interventions, have been increasingly apparent topics of interest in social, academic, and scientific circles. The unusual nature of psilocybin poses many questions in Western culture. Three of them, which will be discussed in the following review, are (1) What is...
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based...
eath is of the most certain and undeniable truths in an existence shrouded by mysteries and unknowns, yet many don't have the opportunity for a meaningful reflection on this matter until the very end of their life.Existential suffering often awaits at death's door while effective solutions remain limited.The reality is that saving lives has been a key pillar of our medical ethos and so the...